Drug:
Reaction: DRUG DOSE OMISSION BY DEVICE
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26492262 |
US |
77 | 1 |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 202 | 26492415 |
US |
||
Expired product administered, Device mechanical issue, Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 203 | 26492464 |
US |
52 | 1 |
Drug dose omission by device, Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 204 | 26494683 |
US |
42 | 2 |
Headache, Drug dose omission by device, Off label use, Device difficult to use, Accidental exposure to product, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 205 | 26494753 |
US |
63 | 2 |
Device difficult to use, Drug dose omission by device, |
||||
| 206 | 26495284 |
US |
2 | |
Device deployment issue, Drug dose omission by device, Device delivery system issue, |
||||
PEGINTERFERON BETA-1A, |
||||
| 207 | 26495679 |
US |
55 | 2 |
Drug dose omission by device, Device breakage, |
||||
SOMATROPIN, SOMATROPIN, |
||||
| 208 | 26495948 |
US |
35 | 2 |
Injection site haemorrhage, Device issue, Drug dose omission by device, Treatment delayed, |
||||
SIBEPRENLIMAB, |
||||
| 209 | 26496350 |
US |
8 | 1 |
Drug dose omission by device, Device use error, Device physical property issue, Device connection issue, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 210 | 26496427 |
KR |
||
Drug dose omission by device, Device information output issue, |
||||
SOMATROPIN, |
||||
| 211 | 26496430 |
CO |
1 | |
Drug dose omission by device, Device mechanical issue, Wrong technique in device usage process, |
||||
SOMATROPIN, |
||||
| 212 | 26485322 |
US |
78 | 2 |
Injection site haemorrhage, Product communication issue, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 213 | 26485869 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 214 | 26486679 |
US |
61 | 1 |
Migraine, Drug dose omission by device, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 215 | 26486781 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 216 | 26487482 |
US |
80 | |
Drug dose omission by device, Circumstance or information capable of leading to device use error, Off label use, Device delivery system issue, |
||||
ALBUTEROL SULFATE, |
||||
| 217 | 26487583 |
CL |
||
Device material issue, Device issue, Device leakage, Drug dose omission by device, |
||||
SOMATROPIN, |
||||
| 218 | 26487591 |
US |
29 | 2 |
Accidental exposure to product, Drug dose omission by device, Device leakage, Device malfunction, |
||||
SECUKINUMAB, |
||||
| 219 | 26487726 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 220 | 26487986 |
US |
78 | |
Drug dose omission by device, Incorrect dose administered by device, Device difficult to use, Device delivery system issue, No adverse event, |
||||
TESTOSTERONE GEL, 1%, VALSARTAN, VALSARTAN ORAL, FENOFIBRATE, |
||||
| 221 | 26488508 |
US |
2 | |
Pneumothorax, Lung neoplasm malignant, Bronchiolitis, Asthma, Dysphonia, Dyspnoea, Drug dose omission by device, Off label use, Wrong technique in product usage process, |
||||
AMIKACIN, AMIKACIN, AMIKACIN, |
||||
| 222 | 26488665 |
US |
||
Fatigue, Illness, Drug dose omission by device, Device delivery system issue, Device mechanical issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 223 | 26488795 |
US |
||
Drug dose omission by device, Expired product administered, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 224 | 26489736 |
US |
||
Drug dose omission by device, Device malfunction, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 225 | 26489827 |
US |
27 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 226 | 26489890 |
US |
||
Drug dose omission by device, Device delivery system issue, Device mechanical issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, TESTOSTERONE, |
||||
| 227 | 26490256 |
US |
34 | 2 |
Injection site bruising, Injection site pain, Injection site mass, Drug dose omission by device, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 228 | 26490517 |
US |
32 | 2 |
Injection site reaction, Injection site pain, Weight decreased, Device malfunction, Drug dose omission by device, |
||||
FREMANEZUMAB-VFRM, |
||||
| 229 | 26490748 |
CO |
1 | |
Drug dose omission by device, Device physical property issue, |
||||
SOMATROPIN, |
||||
| 230 | 26490753 |
KR |
6 | 1 |
Drug dose omission by device, Device power source issue, Product prescribing error, |
||||
SOMATROPIN, |
||||
| 231 | 26490758 |
CO |
1 | |
Drug dose omission by device, Device mechanical issue, |
||||
SOMATROPIN, |
||||
| 232 | 26490926 |
CO |
11 | 1 |
Product preparation issue, Drug administered in wrong device, Incorrect dose administered by device, Accidental overdose, Device use error, Drug dose omission by device, Device mechanical issue, Device leakage, |
||||
SOMATROPIN, |
||||
| 233 | 26491267 |
US |
2 | |
Device defective, Device deployment issue, Device delivery system issue, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Device malfunction, |
||||
SECUKINUMAB, |
||||
| 234 | 26491486 |
AR |
7 | 1 |
Drug dose omission by device, Device information output issue, Device delivery system issue, Device mechanical issue, |
||||
SOMATROPIN, |
||||
| 235 | 26491487 |
CO |
2 | |
Device information output issue, Drug dose omission by device, |
||||
SOMATROPIN, |
||||
| 236 | 26491523 |
CO |
1 | |
Device delivery system issue, Device use issue, Product communication issue, Incorrect dose administered by device, Drug dose omission by device, |
||||
SOMATROPIN, |
||||
| 237 | 26480286 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, BUDESONIDE, |
||||
| 238 | 26480330 |
US |
12 | |
Device malfunction, Wrong technique in product usage process, Exposure via skin contact, Product use issue, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 239 | 26480349 |
US |
79 | |
Drug dose omission by device, Wrong technique in product usage process, Device malfunction, Device delivery system issue, No adverse event, |
||||
TIOTROPIUM BROMIDE, |
||||
| 240 | 26480389 |
US |
33 | |
Device malfunction, Drug dose omission by device, Intentional product use issue, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 241 | 26480403 |
US |
64 | |
Dyspnoea, Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, |
||||
| 242 | 26480413 |
US |
1 | |
Blood cholesterol esterase increased, Glycosylated haemoglobin increased, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 243 | 26480581 |
US |
41 | |
Device malfunction, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 244 | 26480632 |
US |
||
Device malfunction, Product use issue, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 245 | 26480746 |
US |
23 | |
Drug delivery system malfunction, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Wrong technique in device usage process, |
||||
INFLIXIMAB-DYYB, LEVONORGESTREL, |
||||
| 246 | 26481133 |
US |
75 | 2 |
Device difficult to use, Drug dose omission by device, Injection site pain, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 247 | 26481268 |
US |
78 | |
Drug dose omission by device, Expired product administered, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 248 | 26481532 |
US |
69 | 2 |
Incorrect dose administered by device, Device malfunction, Drug dose omission by device, |
||||
PEGFILGRASTIM, PEGFILGRASTIM, |
||||
| 249 | 26481917 |
US |
18 | |
Injection site pain, Device issue, Device defective, Incorrect dose administered by device, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Product use issue, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 250 | 26481933 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 251 | 26481939 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 252 | 26481943 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 253 | 26481949 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 254 | 26481950 |
US |
1 | |
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Wrong technique in device usage process, Product tampering, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 255 | 26481951 |
US |
||
Product use in unapproved indication, Device delivery system issue, Drug dose omission by device, Device issue, Product deposit, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 256 | 26481953 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 257 | 26481955 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 258 | 26481956 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, Product tampering, Wrong technique in device usage process, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 259 | 26481958 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 260 | 26481962 |
US |
||
Drug dose omission by device, Device delivery system issue, Device issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 261 | 26481964 |
US |
||
Drug dose omission by device, Product use issue, Device delivery system issue, Device defective, Product tampering, Wrong technique in device usage process, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 262 | 26481966 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Device issue, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 263 | 26481969 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 264 | 26481972 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Device breakage, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 265 | 26481974 |
US |
||
Product use in unapproved indication, Device delivery system issue, Drug dose omission by device, Device defective, Wrong technique in device usage process, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 266 | 26481976 |
US |
||
Product use issue, Drug dose omission by device, Device breakage, Device delivery system issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 267 | 26482052 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 268 | 26482053 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 269 | 26482054 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 270 | 26482056 |
US |
||
Illness, Infection, Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 271 | 26482057 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 272 | 26482058 |
US |
1 | |
Drug dose omission by device, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 273 | 26482060 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 274 | 26482077 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 275 | 26482079 |
US |
||
Drug dose omission by device, Device delivery system issue, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 276 | 26482080 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 277 | 26482082 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 278 | 26482084 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device defective, Product tampering, Wrong technique in device usage process, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 279 | 26482085 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 280 | 26482087 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 281 | 26482090 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 282 | 26482092 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 283 | 26482095 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Product tampering, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 284 | 26482098 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 285 | 26482100 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device defective, Product tampering, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 286 | 26482102 |
US |
||
Malaise, Dry eye, Dry mouth, Product use in unapproved indication, Drug dose omission by device, Device defective, Device occlusion, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 287 | 26482107 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 288 | 26482108 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 289 | 26482109 |
US |
||
Drug dose omission by device, Device delivery system issue, Device occlusion, Device mechanical issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 290 | 26482110 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 291 | 26482162 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Wrong technique in device usage process, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 292 | 26482164 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Wrong technique in device usage process, Device delivery system issue, Device leakage, Device mechanical issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 293 | 26482170 |
US |
||
Ankle fracture, Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 294 | 26482173 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Product communication issue, Device delivery system issue, Device occlusion, Device mechanical issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 295 | 26482175 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 296 | 26482176 |
US |
||
Hypersensitivity, Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 297 | 26482178 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Device issue, Product communication issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 298 | 26482179 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Wrong technique in device usage process, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 299 | 26482180 |
US |
||
Dyspnoea, Product use in unapproved indication, Drug dose omission by device, Wrong technique in device usage process, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 300 | 26482181 |
US |
||
Product use issue, Drug dose omission by device, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28